₹-0.45
(Market cap
₹4,673 Cr
Recently Viewed
Clear AllMarket cap
₹4,673 Cr
Revenue (TTM)
₹53 Cr
P/E Ratio
--
P/B Ratio
-11
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹-268 Cr
ROE
0 %
ROCE
-311.9 %
Industry P/E
49.96
EV/EBITDA
-23.3
Debt to Equity
-1.2
Book Value
₹-13.1
EPS
₹-7.9
Face value
1
Shares outstanding
324,521,588
CFO
₹-1,956.47 Cr
EBITDA
₹-2,150.82 Cr
Net Profit
₹-2,150.70 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sun Pharma Adv Resrc
| 7.1 | 24.8 | 12.5 | -3.9 | -9.6 | -2.7 | -6.8 |
|
BSE Healthcare
| 0.0 | 2.7 | 4.4 | 4.2 | 24.0 | 13.2 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sun Pharma Adv Resrc
| -33.0 | -34.8 | 37.5 | -27.3 | 45.9 | 23.7 | -17.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharma Adv Resrc
|
144.1 | 4,673.1 | 53.1 | -267.9 | -448.6 | -- | -- | -11.0 |
| 2,374.4 | 19,426.4 | 1,215.1 | 284.8 | 28.7 | 21.1 | 67.7 | 12.8 | |
| 764.3 | 15,008.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 23.9 | 2.8 | |
| 361.2 | 13,845.1 | 2,051.5 | 180.5 | 11.6 | 7.7 | 68.6 | 3.6 | |
| 667.8 | 16,556.6 | 5,092.5 | 545.5 | 15.9 | 14.1 | 30.4 | 3.7 | |
| 1,055.7 | 18,914.0 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.1 | 2.2 | |
| 1,560.7 | 17,896.3 | 1,419.3 | 20.1 | 8.4 | 0.5 | 890.3 | 3.1 | |
| 150.8 | 20,038.4 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.5 | |
| 444.7 | 17,870.4 | 3,720.2 | 352.1 | 13.7 | 8.2 | 50.8 | 3.8 | |
| 1,407.7 | 22,869.2 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1039.5 | 4.9 |
3 min read•By Research Desk
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and... immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India. Read more
Incorporated
2006
Chairman
Dilip S Shanghvi
Managing Director
--
Group
Sun Pharma
Headquarters
Vadodara, Gujarat
Website
Looking for more details about Sun Pharma Advanced Research Company Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsClarification Regarding Increase In Volume
27-Mar-2026No News & Announcements are available.
The share price of Sun Pharma Advanced Research Company Ltd is ₹144.05 (NSE) and ₹144.00 (BSE) as of 21-Apr-2026 IST. Sun Pharma Advanced Research Company Ltd has given a return of -9.57% in the last 3 years.
Since, TTM earnings of Sun Pharma Advanced Research Company Ltd is negative, P/E ratio is not available.
The P/B ratio of Sun Pharma Advanced Research Company Ltd is -10.99 times as on 21-Apr-2026, a 397 discount to its peers’ median range of 3.70 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
-22.14
|
|
2024
|
0.00
|
95.47
|
|
2023
|
0.00
|
11.36
|
|
2022
|
0.00
|
-39.75
|
|
2021
|
0.00
|
-22.07
|
The 52-week high and low of Sun Pharma Advanced Research Company Ltd are Rs 204.40 and Rs 108.00 as of 22-Apr-2026.
Sun Pharma Advanced Research Company Ltd has a market capitalisation of ₹ 4,673 Cr as on 21-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sun Pharma Advanced Research Company Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.